Recent Finacing
Recent Raise
Avidicure develops AVC-Boosters—dual-agonist, avidity-engineered multifunctional antibodies—using a proprietary antibody-engineering and in-silico design platform to create plug-and-play targeted cancer monotherapies including TROP2-targeting AVC-S-101 for NSCLC.
